Halting Our Brain's Slow Deterioration - Dr. Tom O'Bryan

Event Information

Share this event

Date and Time



Inland Realty Conference Room

2901 Butterfield Road

Legacy Room

Oak Brook, IL 60523

View Map

Event description


* as a reminder, these events are for licensed healthcare practitioners only, thank you for your understanding.

An Ounce of Prevention Is Worth a Pound of Protocols:

Halting Our Brains Slow Deterioration

In Clinical Practice, patients suffering with fears of brain dysfunction present daily. No one is getting answers to “what do I do”. Auto-immunology is an emerging specialty within the discipline of Immunologyi. Its study invites a paradigm shift (thinking completely differently)ii as to why our immune system begins attacking our own tissue. The original theories of the 20th century about how and why our immune system does what it does were developed at a time when the human body was believed to be largely sterile. We now know that is not true. It is more likely that the autoantibodies detected in patients with brain dysfunction are generated in response to perceived pathogens (bacteria, molds, toxic chemicals, foods,…) rather than to ‘self’-your brain is trying to protect you from somethingiii. The million-dollar question is ‘what is it trying to protect you from’? Besides the traditional pathogens of our ancestors (bacteria, parasites, viruses, molds and fungi), numerous studies associate environmental toxins in today’s world as potential initiators of the autoimmune cascadeiv. We will explore the mechanisms of why the immune system, trying to protect the brain, becomes activated and ends up attacking brain tissuev.

Whether it manifests as Alzheimer’s Disease, or headaches, Multiple Sclerosis or Brain Fatigue, Brain Fog or Anxiety, the mechanisms that initiate and ‘fuel’ these conditions is often predictable and identifiable. In recent years, several studies have revealed the importance of early detection of autoantibodies as predictors for brain diseasevi vii viii ix. Predictive Autoimmunity now gives us the tools to identify the underlying mechanisms years before brain damage is extensive enough to produce substantial symptomatology and a diagnosed brain disease.

This Presentation will give an in-depth understanding of:

• What genetics have to do with brain deterioration

• The triggers and mechanisms of action creating the autoimmune cascade that eventually manifests as an autoimmune disease.

• Identifying if a patient’s brain is under attack

• Simple tests that will tell us where we stand

• Essential components of treatment protocols


i Autoimmunity. 2017 Jun;50(4):269-274. doi: 10.1080/08916934.2017.1305361. Epub 2017

Mar 23.Is autoimmunology a discipline of its own? A big data-based bibliometric and

scientometric analyses. Watad A, et.al

ii J Neurovirol. 2016 Feb;22(1):22-32. doi: 10.1007/s13365-015-0357-8. Epub 2015 Jun 20.

Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities:

role of gastrointestinal microbiota. Dobbs SM ,et.al.

iii Kothur K, Wienholt L, Mohammad SS, Tantsis EM, Pillai S, Britton PN, Jones CA, Angiti RR,

Barnes EH, Schlub T, Bandodkar S, Brilot F, Dale RC.

Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison

of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis. PLoS One. 2016 Aug 30;11(8)

iv Inflammatory disease and the human microbiome. Proal AD, Albert PJ, Marshall TG. Discov

Med. 2014 May;17(95):257-65. Review.

v Kobeissy F, Moshourab RA. Autoantibodies in CNS Trauma and Neuropsychiatric Disorders: A

New Generation of Biomarkers. In Kobeissy FH, editor. Brain Neurotrauma: Molecular,

Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis;

2015. Chapter 29.

vi Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies. Pérez D,

Gilburd B, Cabrera-Marante Ó, Martínez-Flores JA, Serrano M, Naranjo L, Pleguezuelo D,

Morillas L, Shovman O, Paz-Artal E, Shoenfeld Y, Serrano A. Clin Chem Lab Med. 2017 Jun 17

vii Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy

after Kidney Transplantation. Berthoux F, Suzuki H, Mohey H, Maillard N, Mariat C, Novak J,

Julian BA. J Am Soc Nephrol. 2017 Jun;28(6):1943-1950

viii Thyroglobulin antibodies as a potential predictive marker of papillary thyroid carcinoma in

patients with indeterminate cytology. Karatzas T, Vasileiadis I, Zapanti E, Charitoudis G,

Karakostas E, Boutzios G. Am J Surg. 2016 Nov;212(5):946-952

Date and Time


Inland Realty Conference Room

2901 Butterfield Road

Legacy Room

Oak Brook, IL 60523

View Map

Save This Event

Event Saved